FDA Stymies Nicotine Pouch Fast-Track, Citing Addiction Worries; Blow to PMI's Zyn Growth
Summary
The U.S. Food and Drug Administration (FDA) is delaying fast-track approval for several nicotine pouch products, including Philip Morris International's (PM) top-selling Zyn, due to concerns over potential risks to new users, particularly children, and a lack of clear scientific evidence. This regulatory hurdle is a significant setback for PM, which has pending applications for newer Zyn versions and relies heavily on smoke-free products for growth, as noted in its recent 10-K. Nicotine pouches are the fastest-growing nicotine product in the U.S., with PM's Zyn sales more than doubling in 2025. While Altria's (MO) on! PLUS received approval, the broader delay impacts market access in the world's largest market for smoking alternatives and represents a material blow to PM's strategic shift. Investors should monitor further FDA decisions and how PM adapts its product development and market strategies.
At the time of this announcement, PM was trading at $165.34 on NYSE in the Trade & Services sector, with a market capitalization of approximately $257.4B. The 52-week trading range was $142.11 to $191.30. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.